Therapeutic effects of Xianlinggubao capsules on knee function, inflammatory response, and bone metabolism in elderly patients with degenerative knee osteoarthritis.
Yi Guan, Yemei Gao
✦ AI-curated · Sources linked
In 30 seconds
This randomised controlled trial evaluated Xianlinggubao (XLGB) capsules added to celecoxib in 100 elderly patients with degenerative knee osteoarthritis. Compared with celecoxib alone, the combination group had lower post-treatment inflammatory and pain-related markers, lower VAS and WOMAC scores, and higher bone-metabolism markers and Lysholm scores; all reported between-group differences had p < 0.05. Adverse-reaction incidence did not differ significantly between groups (p > 0.05). The findings suggest potential benefits across symptoms, knee function, and measured bone metabolism, although the abstract does not provide effect sizes for these outcomes.
Key findings
- The trial randomised 100 elderly patients, with 50 assigned to celecoxib alone and 50 to celecoxib plus XLGB.
- The XLGB group had lower VAS and WOMAC scores and higher Lysholm scores than controls after treatment (all p < 0.05).
- Inflammatory and pain-related markers were lower, while BGP, OPG, and BALP were higher, with XLGB plus celecoxib (all p < 0.05).
- Adverse-reaction incidence did not differ significantly between groups (p > 0.05).
Why it matters
The results indicate that adding XLGB to celecoxib may improve patient-reported pain and function while also changing measured inflammatory and bone-metabolism markers in elderly patients with degenerative knee osteoarthritis. Considering both clinical scores and laboratory outcomes may help frame further evaluation of this adjunct, while the absence of reported effect sizes limits assessment of the magnitude of benefit.
What to keep in mind
The abstract reports no effect sizes for the between-group differences, limiting assessment of their magnitude.